Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2025 (Transaction Date: March 5, 2025)
Subject: Disclosure of a transaction in own shares (Share Buyback).
Key Financial Metrics
This filing reports on a specific share repurchase transaction rather than comprehensive financial performance. Key metrics include:
- Shares Purchased (March 5, 2025): 782,440 ordinary shares.
- Price Range: Lowest 1,475.50p; Highest 1,494.50p.
- Volume-Weighted Average Price (VWAP): 1,484.32p.
- Trading Venue: London Stock Exchange (XLON).
- Programme Status: Part of an existing buyback programme under a non-discretionary agreement with Citigroup Global Markets Limited (entered Feb 24, 2025).
- Cumulative Purchases (since Feb 24, 2025): 5,821,342 ordinary shares.
- Treasury Shares Held: 174,891,645.
- Shares in Issue (excluding Treasury): 4,140,285,785.
- Total Voting Rights: 4,140,285,785.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing details a reduction in the number of shares in issue and an increase in treasury shares held by the company. There are no material changes to the company's financial position, operations, or capital structure outside of this specific share repurchase activity.
Guidance, Outlook, and Risks
Management Commentary: The purchase was executed pursuant to a non-discretionary agreement. The shares are held as Treasury shares.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2023 Annual Report on Form 20-F and Q4 2024 Results.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme.
- Confirm the impact of the 174,891,645 treasury shares on earnings per share (EPS) calculations.
- Review the non-discretionary agreement terms announced on February 24, 2025, for duration and total value limits.
- Check the latest Form 20-F for updated risk factors referenced in the cautionary statement.